Literature DB >> 16522689

Extracellular matrix metalloproteinase inducer regulates metalloproteinases in human uterine endometrium.

A G Braundmeier1, A T Fazleabas, B A Lessey, H Guo, B P Toole, R A Nowak.   

Abstract

CONTEXT: Endometrial remodeling occurs during each menstrual cycle in women and also during the establishment of endometriosis. Both processes involve the production of metalloproteinases (MMPs) by uterine endometrial cells.
OBJECTIVE: The objective of this study was to determine whether tissue remodeling and endometrial invasion involve activation of MMPs by extracellular matrix metalloproteinase inducer (EMMPRIN). MAIN OUTCOME MEASURES: EMMPRIN expression was examined by immunohistochemistry and real-time PCR in ectopic and eutopic endometria. For functional assays, human uterine fibroblasts were treated in the absence or presence of IL-1beta (10 ng/ml) or purified native EMMPRIN (0.5 or 1 microg/ml) for 24 h. Cellular RNA and conditioned medium were assayed by real-time PCR or immunoblotting.
RESULTS: EMMPRIN protein localized to epithelial and fibroblast cells of eutopic and ectopic endometria. The pattern of localization was regulated by ovarian hormones. EMMPRIN mRNA levels varied throughout the menstrual cycle in parallel with the cyclic changes in estradiol. EMMPRIN treatment (0.5 microg/ml) of human uterine fibroblast cells stimulated MMP-1 (5.23-fold) and MMP-2 (8.55-fold), but not MMP-3, mRNA levels over levels in control cells (P < 0.05). EMMPRIN treatment (1 microg/ml) stimulated endogenous EMMPRIN (1.6-fold) mRNA levels (P > 0.05). IL-1beta stimulated MMP-1 (5.6-fold), MMP-2 (2.8-fold), and MMP-3 (75-fold) gene expression, but not EMMPRIN, over levels in control cells (P < 0.05). Both EMMPRIN and IL-1beta treatments stimulated MMP-1, -2, and -3, but not EMMPRIN protein secretion, with 0.5 microg/ml producing the greatest response.
CONCLUSIONS: The ability of EMMPRIN to stimulate MMP secretion by endometrial fibroblasts indicates its potential role in uterine remodeling and the pathogenesis of endometriosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16522689     DOI: 10.1210/jc.2005-0601

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  EMMPRIN is secreted by human uterine epithelial cells in microvesicles and stimulates metalloproteinase production by human uterine fibroblast cells.

Authors:  A G Braundmeier; C A Dayger; P Mehrotra; R J Belton; R A Nowak
Journal:  Reprod Sci       Date:  2012-06-22       Impact factor: 3.060

2.  Extracelluar matrix metalloproteinase as a novel target for pancreatic cancer therapy.

Authors:  Hyunki Kim; Guihua Zhai; Zhiyong Liu; Sharon Samuel; Nemil Shah; Emily E Helman; Joseph A Knowles; Cecil R Stockard; Naomi S Fineberg; William E Grizzle; Tong Zhou; Kurt R Zinn; Eben L Rosenthal
Journal:  Anticancer Drugs       Date:  2011-10       Impact factor: 2.248

3.  Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.

Authors:  Hyunki Kim; Guihua Zhai; Sharon L Samuel; Christopher J Rigell; Heidi R Umphrey; Samir Rana; Cecil R Stockard; Naomi S Fineberg; Kurt R Zinn
Journal:  Mol Cancer Ther       Date:  2011-12-27       Impact factor: 6.261

4.  Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers.

Authors:  Hyunki Kim; Christopher J Rigell; Guihua Zhai; S Kyle Lee; Sharon L Samuel; Amber Martin; Heidi R Umphrey; Cecil R Stockard; T Mark Beasley; Donald J Buchsbaum; Long Shan Li; David A Boothman; Kurt R Zinn
Journal:  Mol Imaging Biol       Date:  2013-07-09       Impact factor: 3.488

5.  Stimulation of GPR30 increases release of EMMPRIN-containing microvesicles in human uterine epithelial cells.

Authors:  Lindsey A Burnett; Mallory M Light; Pavni Mehrotra; Romana A Nowak
Journal:  J Clin Endocrinol Metab       Date:  2012-09-25       Impact factor: 5.958

6.  Dynamic contrast-enhanced MRI evaluates the early response of human head and neck tumor xenografts following anti-EMMPRIN therapy with cisplatin or irradiation.

Authors:  Hyunki Kim; Yolanda E Hartman; Guihua Zhai; Thomas K Chung; Melissa L Korb; Timothy M Beasley; Tong Zhou; Eben L Rosenthal
Journal:  J Magn Reson Imaging       Date:  2015-02-20       Impact factor: 4.813

7.  Extracellular matrix metalloproteinase inducer expression in the baboon endometrium: menstrual cycle and endometriosis.

Authors:  A G Braundmeier; A T Fazleabas; R A Nowak
Journal:  Reproduction       Date:  2010-09-14       Impact factor: 3.906

8.  EMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenografts.

Authors:  J Robert Newman; Emily E Helman; Seena Safavy; Wenyue Zhang; Eben L Rosenthal
Journal:  Cancer Lett       Date:  2008-11-05       Impact factor: 8.679

9.  Expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and its related extracellular matrix degrading enzymes in the endometrium during estrous cycle and early gestation in cattle.

Authors:  Birendra Mishra; Keiichiro Kizaki; Katsuo Koshi; Koichi Ushizawa; Toru Takahashi; Misa Hosoe; Takashi Sato; Akira Ito; Kazuyoshi Hashizume
Journal:  Reprod Biol Endocrinol       Date:  2010-06-11       Impact factor: 5.211

10.  Basigin-mediated gene expression changes in mouse uterine stromal cells during implantation.

Authors:  Li Chen; Robert J Belton; Romana A Nowak
Journal:  Endocrinology       Date:  2008-10-01       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.